<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83991">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922349</url>
  </required_header>
  <id_info>
    <org_study_id>1314.9</org_study_id>
    <nct_id>NCT01922349</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability and pharmacokinetics of  single and multiple oral doses of BI 113608 in
      healthy Chinese, Japanese and Caucasian male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number (%) of subjects with drug-related adverse events</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant findings in physical examination</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant findings in vital signs</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in electrocardiogramm (ECG) results</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with significant changes from baseline laboratory measurements</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusing capacity of the lung for carbon monoxide (DLCO)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration in plasma)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma from time 0 to time of last quantifiable data point)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma after the first dose)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady state)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval t, expressed as ratio of Cmax at steady state and after single dose)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose administration over a uniform dosing interval t, expressed as ratio of AUC at steady state and after single dose)</measure>
    <time_frame>up to 23 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo (Multiple dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4, Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5, Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6, Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Single dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Medium dose (Multiple dosing)</description>
    <arm_group_label>Dose 5, Multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Multiple dosing)</description>
    <arm_group_label>Placebo (Multiple dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose (Multiple dosing)</description>
    <arm_group_label>Dose 4, Multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Single dosing)</description>
    <arm_group_label>Placebo (Single dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>High dose (Single dosing)</description>
    <arm_group_label>Dose 3, Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Medium dose (Single dosing)</description>
    <arm_group_label>Dose 2, Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>Low dose (Single dosing)</description>
    <arm_group_label>Dose 1, Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 113608</intervention_name>
    <description>High dose (Multiple dosing)</description>
    <arm_group_label>Dose 6, Multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        -Healthy male volunteers according to the following criteria: Based upon a complete
        medical history, including the physical examination, vital signs (Blood Pressure, Pulse
        Rate), 12-lead Electrocardiogram, clinical laboratory tests

          -  Chinese ethnicity, Japanese ethnicity according to the following criteria Japanese;
             born in Japan, be a current Japanese passport holder, have lived outside of Japan &lt;10
             years, and have parents and grandparents who were all born in Japan Chinese; ethnic
             Chinese, born in China or ethnic Chinese born outside of China, and a descendent of 4
             ethnic Chinese grandparents who were all born in China

          -  Caucasian

          -  Age older than 20 and younger than 45 years

          -  Normal lung function testing

          -  Normal peripheral oxygen saturation as determined by non-invasive pulse oxymetry

          -  Body Mass Index more than 18.5 and Body Mass Index less than 25 kg/m2 for Japanese
             and Chinese

          -  Body Mass Index more than 18.5 and Body Mass Index less than 29.9 kg/m2 for
             Caucasians

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation.

        Exclusion criteria:

          -  Any finding of the medical examination (including Blood Pressure, Pulse Rate and
             Electrocardiogram) deviating from normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures, migraine, stroke or psychiatric disorders) within the past 6 month

          -  History of relevant orthostatic hypotension, fainting spells or blackouts.

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial or that
             prolong the QT/QTc interval based on the knowledge at the time of protocol
             preparation within 10 days prior to administration or during the trial

          -  Participation in another trial with an investigational drug within two months prior
             to administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (more than 20 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms);

          -  A history of additional risk factors for Torsades de pointes (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1314.9.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
